Drew Armstrong

Drew Armstrong is an experienced health care journalist with nearly two decades in the field. He currently serves as the Executive Editor of Endpoints News and joined the newsroom in 2022. Prior to this role, he had a 12-year career at Bloomberg News where he led the U.S. coverage of the Covid-19 pandemic and developed their 'Prognosis' health care vertical. He also managed a team of journalists covering various aspects of the American health care system. Drew has been recognized by multiple journalism awards for his work as a writer, editor, and data project manager, and he frequently appears on television and radio to discuss his reporting. He lives in the New York City area with his family.

Biography:  https://endpts.com/author/drew-armstrong/

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • Amgen has discontinued development of its experimental weight loss pill.
  • Amgen plans a late-stage trial for MariTide in obesity and a stage two trial in diabetes treatment.
  • Amgen plans to rapidly move forward with a final-stage program as well as boost manufacturing capacity for the experimental drug.
  • MariTide is in an ongoing midstage trial and initial data will be released later this year.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

Broke On: Friday, 03 May 2024 Amgen, a California-based biotech company, announced its focus on MariTide, an injectable obesity drug in Phase 2 trials with promising interim results. Patients lost an average of 14.5% body weight in 12 weeks according to phase one data. Amgen plans late-stage studies and expansion of manufacturing capacity for this differentiated obesity treatment.